PIRS Dana dhuwit perusahaan Pieris Pharmaceuticals, Inc.

Pieris Pharmaceuticals (PIRS) faces significant business risks due to a capital shortage and potential research failures. The cash balance shown on the GURU.Markets temporary chart confirms this trend, with the metric currently standing at 0.26. Anticalin protein patents and lobbying efforts serve as a defense, despite strict FDA oversight. However, the severance of ties with industry behemoths has triggered a prolonged liquidity crisis.
Rincian metrik keuangan lan pasar Pieris Pharmaceuticals, Inc. (PIRS)

Global scaling of the Anticalin protein platform requires colossal expenditures on clinical trials and B2B partnerships. This metric measures the volume of liquid assets, determining the ability of Pieris Pharmaceuticals (PIRS) to finance expansion without external borrowing. By analyzing the cash flow chart on GURU.Markets, an investor assesses the burn rate. Liquidity dynamics directly confirm the issuer's solvency. A stable cash balance guarantees the fundamental stability of the asset.